Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx completes enrollment in Phase III osteoarthritis study
The 302 study for naproxcinod was initiated in April, 2007 and is being conducted by Premier Research Group. This study is a 53-week, randomized, double-blind, efficacy and safety
The 302 study for naproxcinod was initiated in April, 2007 and is being conducted by Premier Research Group. This study is a 53-week, randomized, double-blind, efficacy and safety
The Committee for Medicinal Products for Human Use (CMPH) concluded that another study would be needed to demonstrate eprodisate’s (Kiacta) effectiveness. The company is currently reviewing all of
The blinded, placebo-controlled single ascending dose study, which was conducted in the US under an exploratory investigational new drug application, evaluated the safety and pharmacokinetics of three oral
In the study, Monogram analyzed tissue samples from patients with metastatic breast cancer who were treated with Herceptin, having been selected for such treatment by centralized IHC testing.
The company said that Unite Biomatrix is a novel collagen wound dressing with uncompromised strength to support the natural healing environment. Michael Will, CEO of Pegasus, said: “Receiving
Known as BLOSSOM (behavioral modification and lorcaserin second study for obesity management) and BLOOM-DM (behavioral modification and lorcaserin for overweight and obesity management in diabetes mellitus), these one-year,
Anna Gluskin, president and CEO of Generex, said: “We are excited to secure a significant purchase order in the short time since we announced our collaboration. The Middle
Guerbet submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) in November 2006 seeking marketing approval for Sinerem for the detection and characterization of metastatic
The deal was structured as an asset purchase under which a newly formed subsidiary of Inverness acquired substantially all of the assets of Matritech for aggregate consideration of
Combining Rosetta Genomics know-how and proprietary technologies with Columbia University Medical Center’s expertise in cancer, researchers are expected to screen for microRNAs that may be used as potential